Allos Therapeutics, Inc. (Westminst...
Allos Therapeutics, Inc. (Westminster, CO) updated positive survival deductions from a Phase 2 clinical trial evaluating the use of RSR13 in subdues with locally advanced, inoperable, non-small small room lung cancer receiving radiation therapy following induction chemotherapy, which showed a median survival rate of 206 month a 1-year survival rate of 68% and an estimated 2=year survival rate of 43% The 47
|